Sandoz, Inc. is recalling approximately 250,232 bottles of Ranitidine Hydrochloride Capsules (150mg and 300mg), a prescription medication used to treat stomach acid conditions. The recall was initiated because testing detected trace amounts of N-nitrosodimethylamine (NDMA), an impurity that is classified as a probable human carcinogen. These prescription medications were manufactured in India and distributed across the United States in bottles of 30, 60, and 500 capsules. Consumers should consult with their healthcare provider to discuss alternative treatment options before stopping the medication.
The capsules contain trace amounts of NDMA, a substance that may increase the risk of cancer with long-term exposure. While no immediate injuries or adverse events have been reported for this specific recall, the presence of this impurity exceeds acceptable safety limits.
Refund for unused medication
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.